Point72 Asia Singapore Pte. Ltd. Acquires New Holdings in Repligen Co. (NASDAQ:RGEN)

Point72 Asia Singapore Pte. Ltd. acquired a new stake in Repligen Co. (NASDAQ:RGEN) in the 3rd quarter, Holdings Channel.com reports. The fund acquired 13,976 shares of the biotechnology company’s stock, valued at approximately $2,080,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Champlain Investment Partners LLC grew its position in shares of Repligen by 149.0% in the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after purchasing an additional 850,345 shares during the period. Bank of New York Mellon Corp lifted its stake in Repligen by 21.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock valued at $172,749,000 after acquiring an additional 237,884 shares in the last quarter. Conestoga Capital Advisors LLC lifted its stake in Repligen by 26.7% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock valued at $119,363,000 after acquiring an additional 199,322 shares in the last quarter. Thrivent Financial for Lutherans lifted its stake in Repligen by 6.1% in the 3rd quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock valued at $95,037,000 after acquiring an additional 36,773 shares in the last quarter. Finally, New York State Common Retirement Fund lifted its stake in Repligen by 14.4% in the 3rd quarter. New York State Common Retirement Fund now owns 567,044 shares of the biotechnology company’s stock valued at $84,387,000 after acquiring an additional 71,274 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Stock Up 0.4 %

RGEN stock opened at $150.54 on Monday. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $8.43 billion, a PE ratio of -406.85, a PEG ratio of 4.53 and a beta of 0.96. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $211.13. The business’s 50 day simple moving average is $140.98 and its 200 day simple moving average is $142.41.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. The business had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm’s revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.23 EPS. As a group, research analysts anticipate that Repligen Co. will post 1.52 EPS for the current year.

Insider Buying and Selling at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares of the company’s stock, valued at $20,328,540.80. This represents a 13.70 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 1.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Royal Bank of Canada restated an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. Benchmark restated a “hold” rating on shares of Repligen in a research note on Monday, August 5th. Wells Fargo & Company assumed coverage on Repligen in a research note on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price objective on the stock. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research note on Friday, November 22nd. Finally, Wolfe Research assumed coverage on Repligen in a research note on Thursday, November 14th. They set a “peer perform” rating on the stock. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $190.25.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.